ATE537186T1 - P53-bindendes polypeptid - Google Patents

P53-bindendes polypeptid

Info

Publication number
ATE537186T1
ATE537186T1 AT08153666T AT08153666T ATE537186T1 AT E537186 T1 ATE537186 T1 AT E537186T1 AT 08153666 T AT08153666 T AT 08153666T AT 08153666 T AT08153666 T AT 08153666T AT E537186 T1 ATE537186 T1 AT E537186T1
Authority
AT
Austria
Prior art keywords
binding polypeptide
polypeptide
activity
inhibits
interfere
Prior art date
Application number
AT08153666T
Other languages
English (en)
Inventor
Xin Ludwig Lu
Patricia Kuwabara
David Selwood
Original Assignee
Ludwig Inst For Cancer Res Ltd
Genome Res Ltd
Ucl Cruciform Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0223193A external-priority patent/GB0223193D0/en
Priority claimed from GB0306261A external-priority patent/GB0306261D0/en
Application filed by Ludwig Inst For Cancer Res Ltd, Genome Res Ltd, Ucl Cruciform Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Application granted granted Critical
Publication of ATE537186T1 publication Critical patent/ATE537186T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08153666T 2002-10-07 2003-10-03 P53-bindendes polypeptid ATE537186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223193A GB0223193D0 (en) 2002-10-07 2002-10-07 Polypeptide
GB0306261A GB0306261D0 (en) 2003-03-19 2003-03-19 Polypeptide

Publications (1)

Publication Number Publication Date
ATE537186T1 true ATE537186T1 (de) 2011-12-15

Family

ID=32071253

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03756559T ATE425183T1 (de) 2002-10-07 2003-10-03 P53-bindendes polypeptid
AT08153666T ATE537186T1 (de) 2002-10-07 2003-10-03 P53-bindendes polypeptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03756559T ATE425183T1 (de) 2002-10-07 2003-10-03 P53-bindendes polypeptid

Country Status (9)

Country Link
US (2) US20060100143A1 (de)
EP (2) EP1558638B1 (de)
JP (1) JP2006517787A (de)
AT (2) ATE425183T1 (de)
AU (1) AU2003299132A1 (de)
CA (1) CA2487206A1 (de)
DE (1) DE60326623D1 (de)
HK (1) HK1083220A1 (de)
WO (1) WO2004031229A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514538D0 (en) * 2005-07-14 2005-08-24 Ludwig Inst Cancer Res Variant polypeptide and screening assay
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
GB0716322D0 (en) * 2007-08-21 2007-10-03 Cancer Rec Tech Ltd Crystal structure
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013131019A1 (en) 2012-03-02 2013-09-06 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9873718B2 (en) 2013-05-08 2018-01-23 The Regents Of The University Of California Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
US20180284114A1 (en) * 2015-10-02 2018-10-04 Arizona Board Of Regents On Behalf Of Arizona State University Methods for processing biopolymeric arrays
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397834B1 (de) 1988-10-28 2000-02-02 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1998007876A2 (en) 1996-08-16 1998-02-26 Medical Research Council Self-replicating episomal expression vectors conferring tissue-specific gene expression
KR100272659B1 (ko) 1997-06-28 2000-12-01 김영환 반도체 소자의 금속배선 선폭 측정방법
CA2319089A1 (en) 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
US6582933B1 (en) * 1998-12-03 2003-06-24 Ono Pharmaceutical Co., Ltd. Rel1A binding inhibitor, process for producing the same and utilization thereof
WO2000055175A1 (en) 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
ES2277683T3 (es) * 1999-07-23 2007-07-16 Glaxo Group Limited Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico.
CA2417368A1 (en) 2000-08-04 2002-02-14 Xin Lu Suppressor gene

Also Published As

Publication number Publication date
HK1083220A1 (en) 2006-06-30
EP1558638A2 (de) 2005-08-03
JP2006517787A (ja) 2006-08-03
ATE425183T1 (de) 2009-03-15
DE60326623D1 (de) 2009-04-23
EP1947113B1 (de) 2011-12-14
US20060100143A1 (en) 2006-05-11
WO2004031229A2 (en) 2004-04-15
CA2487206A1 (en) 2004-04-15
AU2003299132A1 (en) 2004-04-23
US20080260756A1 (en) 2008-10-23
EP1558638B1 (de) 2009-03-11
EP1947113A1 (de) 2008-07-23
WO2004031229A3 (en) 2004-09-23
US7745571B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
HK1083220A1 (en) P53 binding polypeptide
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
MX2007001345A (es) Regiones variantes fc.
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
MX224000B (es) Agentes herbicidas para cultivos de arroz tolerantes o resistentes.
DE602004029680D1 (de) Isoformen von gehirn-natriuretischem peptid
NO20043564L (no) Follistatindomene som inneholder proteiner
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK1521831T3 (da) Transgent dyr der udtrykker trunkeret alzheimers tauprotein
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
DE60128701D1 (en) Claudin polypeptide
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
DE69409961T2 (de) Triarylethylenderivate zur therapeutischen verwendung
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
ATE328282T1 (de) Screening-verfahren auf basis der siah-numb- wechselwirkung
DE60238243D1 (de) Polypeptide, abgeleitet von der amyloid vorläuferprotein (app), und ihre verwendungen
WO2003095484A3 (en) Polypeptides increasing p53 expression
WO2006003427A8 (en) A protein involved in carcinoma
TW200635953A (en) Specific binding agents of human angiopoietin-2
SE0200265D0 (sv) Protein complexes
ES1051716Y (es) Cortadora-pulidora de piedras o similares.
ATE538133T1 (de) Replikin-peptide und ihre verwendungszwecke